The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $14.20

Today's change+0.15 +1.07%
Updated September 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $14.20

Today's change+0.15 +1.07%
Updated September 22 4:00 PM EDT. Delayed by at least 15 minutes.

Meridian Bioscience Inc crosses above 50-day moving average

Meridian Bioscience Inc closed up Friday by (U.S.)$0.15 or 1.07% to (U.S.)$14.20 and crossing above its 50-day moving average. Over the last five days, shares have gained 0.71%, but are down 19.77% for the last year to date. Shares have underperformed the S&P 500 by 42.96% during the last year.

Key company metrics

  • Open(U.S.) $14.05
  • Previous close(U.S.) $14.05
  • High(U.S.) $14.25
  • Low(U.S.) $14.05
  • Bid / Ask(U.S.) $12.05 / (U.S.) $16.95
  • YTD % change-19.77%
  • Volume182,144
  • Average volume (10-day)206,768
  • Average volume (1-month)198,825
  • Average volume (3-month)251,888
  • 52-week range(U.S.) $10.75 to (U.S.) $19.85
  • Beta0.85
  • Trailing P/E28.32×
  • P/E 1 year forward21.19×
  • Forward PEG1.25×
  • Indicated annual dividend(U.S.) $0.50
  • Dividend yield3.52%
  • Trailing EPS(U.S.) $0.50
Updated September 22 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.00%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue50544747
Total other revenue--------
Total revenue50544747
Gross profit31342930
Total cost of revenue19211717
Total operating expense46403738
Selling / general / administrative16151616
Research & development4434
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)7----1
Other operating expenses, total--------
Operating income414109
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax414109
Income after tax0965
Income tax, total4533
Net income0965
Total adjustments to net income--------
Net income before extra. items0965
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items0965
Inc. avail. to common incl. extra. items0965
Diluted net income0965
Dilution adjustment--------
Diluted weighted average shares43434342
Diluted EPS excluding extraordinary itemsvalue per share0.010.220.150.13
Dividends per sharevalue per share0.130.130.200.20
Diluted normalized EPSvalue per share0.110.220.150.14